Skip to search formSkip to main contentSkip to account menu

NV1020

A genetically engineered oncolytic virus with potential antineoplastic property. NV1020 is constructed from the herpes simplex virus 1 (HSV-1) by the… 
National Institutes of Health

Related topics

Related topics

1 relation
Simplexvirus

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Response to intra-arterial oncolytic virotherapy with the herpes virus NV1020 evaluated by [18F]fluorodeoxyglucose positron emission tomography and computed tomography.
Oncolytic virotherapy poses unique challenges to the evaluation of tumor response. We hypothesized that the addition of [(18)F… 
2009
2009
Phase II efficacy results using an oncolytic herpes simplex virus (NV1020) in patients with colorectal cancer metastatic to liver (mCRC)
4089 Background: NV1020 is a genetically engineered oncolytic Herpes virus. Published Phase 1 dose-ranging results reported no… 
2008
2008
Imaging characteristics and response after intraarterial administration of the oncolytic herpes virus NV1020 to treat hepatic colorectal metastases
15121 Background: Tumor response to oncolytic viruses may show atypical imaging characteristics compared with other agents… 
2008
2008
Tumor efficacy of an oncolytic herpes simplex virus (NV1020) in patients with colorectal cancer metastatic to liver (mCRC)
15014 Background: Dose-finding safety results are published for NV1020, a genetically engineered oncolytic Herpes simplex virus… 
2007
2007
Effective treatment of human breast tumor in a mouse xenograft model with herpes simplex virus type 1 specifying the NV1020 genomic deletion and the gBsyn3 syncytial mutation enabling high viral…
A new oncolytic and fusogenic herpes simplex virus type 1 (HSV-1) was constructed on the basis of the wildtype HSV-1(F) strain… 
2006
2006
APhase I Study of OncoVEX, a Second-Generation Oncolytic Herpes SimplexVirus Expressing Granulocyte Macrophage Colony-Stimulating Factor
Purpose:To conduct a phase I clinical trial with a second-generation oncolytic herpes simplex virus (HSV) expressing granulocyte… 
2004
2004
Effect of murine liver cell proliferation on herpes viral behavior: Implications for oncolytic viral therapy
Replication‐competent herpes simplex oncolytic viruses are promising anticancer agents that partly target increased DNA synthesis… 
Highly Cited
2002
Highly Cited
2002
Oncolytic viral gene therapy for prostate cancer using two attenuated, replication‐competent, genetically engineered herpes simplex viruses
Attenuated, replication‐competent herpes simplex virus mutants offer an exciting new modality in cancer therapy through their… 
Highly Cited
2001
Highly Cited
2001
Effective treatment of head and neck squamous cell carcinoma by an oncolytic herpes simplex virus.
2000
2000
Strong expression of sialyl-LEx defined by mAb AM-3IS, a prognostic marker after curative resection of stage II and III colorectal carcinomas
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)